Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.

S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

<p>In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.</p>

Science

Health & Fitness

In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.

Share S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

Sign up to save your podcasts

S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL

More shows like OncLive® On Air

JAMA Clinical Reviews

Journal of Clinical Oncology (JCO) Podcast

Research To Practice | Oncology Videos

ASCO Daily News

White Coat Investor Podcast

OncoPharm

ASCO Guidelines

ASCO Education

Lung Cancer Considered

The Uromigos

All-In with Chamath, Jason, Sacks & Friedberg

Oncology Today with Dr Neil Love

The Megyn Kelly Show

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions